Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-10-14
2008-10-07
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S273000, C514S303000, C514S406000, C544S236000, C544S333000, C546S119000, C548S361100
Reexamination Certificate
active
07432266
ABSTRACT:
Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.
REFERENCES:
patent: 4012495 (1977-03-01), Schmiechen et al.
patent: 4193926 (1980-03-01), Schmiechen et al.
patent: 4219551 (1980-08-01), Seidelamnn et al.
patent: 5539111 (1996-07-01), Petzoldt et al.
patent: 5814651 (1998-09-01), Duplantier et al.
patent: 5846514 (1998-12-01), Foster et al.
patent: 5869516 (1999-02-01), Arlt et al.
patent: 5935978 (1999-08-01), Fenton et al.
patent: 6136821 (2000-10-01), Hersperger
patent: 6235736 (2001-05-01), Ina et al.
patent: 6258833 (2001-07-01), Martins et al.
patent: 6334997 (2002-01-01), Foster et al.
patent: 6372777 (2002-04-01), Martins et al.
patent: 6403597 (2002-06-01), Wilson et al.
patent: 6423710 (2002-07-01), Martins et al.
patent: 6495154 (2002-12-01), Tam et al.
patent: 7226930 (2007-06-01), Hopper
patent: 1 251 126 (2002-10-01), None
patent: 1251126 (2002-10-01), None
patent: 1072415 (1998-03-01), None
patent: WO 92/19594 (1992-11-01), None
patent: WO 93/07141 (1993-04-01), None
patent: WO 93/25517 (1993-12-01), None
patent: WO 94/14742 (1994-07-01), None
patent: WO 95/28926 (1995-11-01), None
patent: WO 95/35282 (1995-12-01), None
patent: WO 97/25312 (1997-07-01), None
patent: WO 97/49702 (1997-12-01), None
patent: WO 98/58901 (1998-12-01), None
patent: WO 00/66562 (2000-11-01), None
patent: WO 01/40216 (2001-06-01), None
patent: WO 0140216 (2001-06-01), None
patent: WO 01/58895 (2001-08-01), None
patent: WO 01/68600 (2001-09-01), None
patent: WO 02/45749 (2002-06-01), None
patent: WO 03/087062 (2003-10-01), None
patent: WO 2004/007463 (2004-01-01), None
patent: WO 2004/094411 (2004-11-01), None
Cancer and Metastasis Reviews (1998), 17 (1), 91-106.
A. Maureen Rouhi, Chemical & Engineering News, Feb. 24, 2003, pp. 32-35.
US Pharmacopia #23, national formulary #18, pp. 1843-1844 (1995).
Int'l Search Report and the Written Opinion of the Int'l. Searching Authority, issued Feb. 27, 2006 in PCT Application No. PCT/US2005/036801.
Database Caplus, XP-002294354, Copyright 1988-2001.
Malcom A. Halcrow, et al. “Metal complexes of sterically hindered pyrazolypyridines . . . ”, Polyhedron, vol. 16, No. 124, pp. 4257-4264, 1997.
Database Caplus, XP-002367781, Copyright 1988-2005.
Barad et al. Proc. Natl. Acad. Sci., USA , Dec. 1998 vol. 95, pp. 15020-15025.
Christensen et al. J.Med. Chem, 1998, vol. 41, pp. 821-835.
Crossland, Drugs of the Future, 1998 vol. 13, No. 1.
Database Caplus, XP002294352, Journal of the Chemical Society, Perkins Transactions 1, 1997, vol. 12, pp. 1477-1500 Accession No. 1978-6818.
Database Caplus, XP002294353, Synthetic Communication, 1996, vol. 26, No. 14, pp. 2603-2611.
Database Beilstein, XP002294354, 1996, Acta Crystallographica Sect. B., vol. 52, No. 4, pp. 746-752.
Demnitz et al. Molecules, 1998, vol. 3 pp. 107-119.
Egawa et al Jpn. J Pharmacol, 1997, Nov. 75, (3) pp. 275-281.
Halrow et al. Polyhedron, 1997, vol. 16, No. 24, pp. 4257-4264.
Houslay et al. 1998, Advance in Pharmacology, 1998, vol. 44, pp. 225-342.
Japanese Patent Abstract No. 2001-039954, (Feb. 13, 2001).
Keller et al. Chem. Pharm. Bull, 2001, 49 (8) 1009-1017.
Krause et al Xenobiotica, 1998, vol. 18, No. 5, pp. 561-571.
Kusters et al. Journal of Chromatopgraphy, 1996, vol. 737, pp. 333-337.
Langlois et al., 1997, Synthetic Communications, 27 (18), pp. 3133-3144.
Lourenco et al. Nuclear Medicine & Biology, 2001, vol. 28, pp. 347-358.
Marivet et al. J. Med. Chem. 1989, 32, pp. 1450-1457.
Martin, Idrugs, 2001, 4(3), pp. 312-338.
Meyers et al. J. Org. Chem., 1993, vol. 58, pp. 36-42.
Morgan et al. Biochemical Pharmacology, 1993, 45 (12) 2373-80 pp. 23-27 CAS Abstract Only Considered, Oct. 23, 2007.
Nagakura et al. British Journal of Pharmacology, 2002, 135, pp. 1783-1793.
Osby et al. Tetrahedron Letters, 1985, vol. 26, No. 52, pp. 6413-6416.
Patent Abstracts of Japan, vol. 2000, No. 19, Jun. 5, 2001 & JP 2001 039954 A (Tomono Agrica Co.,Ltd.), Feb. 13, 2001 p. 123.
Robichaud et al. Neuropharmacology, 1999, 38, pp. 289-297.
Schmiechen et al. Psychopharmacology, 1990, 102 (1) pp. 17-20.
Wang et al. Biochemical & Biophysical Research Communications, 1997, pp. 234,320-324.
Zhang et al. Neuropsychopharmacology, 2000, 23, pp. 198-204.
Zhang et al. Psychopharmacology DOI, 2000, 10.
Conticello Richard D.
Dunn Robert F.
Hopper Allen
Kuester Erik Mikal
Anderson Rebecca
Barker Michael P.
Memory Pharmaceuticals Corporation
Millen White Zelano & Branigan P.C.
LandOfFree
Phosphodiesterase 4 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphodiesterase 4 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphodiesterase 4 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3996413